Soliris(R) Reduced Measures of Thrombosis and Inflammation, & Decreased Indicators of Pulmonary Hypertension, Patients with PNH
CHESHIRE, Conn., Dec. 9 /PRNewswire-FirstCall/ -- Soliris(R) (eculizumab),a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc.(Nasdaq: ALXN), was observed by investigators to reduce blood measuresassociated with undiagnosed blood clots and inflammation in patients with PNH.